Loading
Life sciences · Journal article
Biomacromolecules · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Tumor therapy is challenged by heterogeneity, drug resistance, and systemic toxicity. Targeting tumor redox imbalance using pro-oxidants offers a promising strategy, but natural pro-oxidants such as curcumin (Cur) and cinnamaldehyde (CA) suffer from poor solubility and bioavailability. Here, we developed two redox dual-responsive Cur-based polyprodrug nanoparticles, PCSC NPs with thioether linkages and PCSSC NPs with disulfide bonds, incorporating a ROS-sensitive CA-derived crosslinker (CASOH). The distinct linkages enable sequential ROS/GSH-responsive cleavage and programmed drug release, while CASOH promotes rapid nanoparticle disassembly. This design triggers a self-amplifying oxidative stress cascade, leading to lipid peroxidation, GPX4 downregulation, mitochondrial membrane depolarization, and increased lysosomal membrane permeabilization, thereby activating apoptotic and autophagic cell death. In 4T1 tumor-bearing mice, both NPs achieved efficient tumor accumulation, potent antitumor activity with up to 85% tumor inhibition, and minimal systemic toxicity. These findings demonstrate a redox-programmable polyprodrug platform for adaptive drug release and amplified oxidative damage in cancer therapy.